RE: Could they already be in a bidding war AVA6103?3 Feb 2025 15:05
As of now, there is no publicly available information indicating that Avacta is engaged in a bidding war for a partnership concerning AVA6103. AVA6103 is a novel, potent peptide drug conjugate developed using Avacta's pre|CISION™ platform, designed to enable tumor-specific delivery of a topoisomerase I inhibitor to induce DNA damage and drive cancer cell death.
AVACTA.COM
Regarding disclosure obligations, UK companies are generally required to inform shareholders of significant developments that could impact the company's valuation or operations. However, specific disclosure requirements can vary based on factors such as the company's listing status and the nature of the information. For instance, the Companies (Shareholders’ Rights) Regulations 2009 outline certain rights and obligations concerning shareholder information.
LEGISLATION.GOV.UK
In summary, while there is no current public evidence of Avacta being involved in a bidding war for an AVA6103 partnership, the company would be obligated to disclose such material information to shareholders in accordance with UK regulations if it were to occur.